Ignite Creation Date:
2025-12-24 @ 2:38 PM
Ignite Modification Date:
2026-01-29 @ 3:18 PM
Study NCT ID:
NCT02659059
Status:
COMPLETED
Last Update Posted:
2023-04-05
First Post:
2016-01-15
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer
Sponsor:
Bristol-Myers Squibb
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-02-15
Start Date Type:
ACTUAL
Primary Completion Date:
2018-06-22
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-03-07
Completion Date Type:
ACTUAL
First Submit Date:
2016-01-15
First Submit QC Date:
None
Study First Post Date:
2016-01-20
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2021-06-10
Results First Submit QC Date:
None
Results First Post Date:
2021-07-22
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2019-07-09
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2023-03-07
Last Update Post Date:
2023-04-05
Last Update Post Date Type:
ACTUAL